Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Prostate Imaging Using MRI +/- Contrast Enhancement

NCT04571840 · View on ClinicalTrials.gov ↗

Study Summary

This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that requires injection of IV contrast (the current standard practice) versus MRI scans that can be performed without IV contrast in the detection of prostate cancer.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Multiparametric MRI +/- prostate biopsy
  • DIAGNOSTIC_TEST Biparametric MRI +/- prostate biopsy

Study Locations (20)

Other

  • Centro de Urologia — Buenos Aires
  • Monash University — Melbourne
  • Peter MacCallum Cancer Centre — Melbourne E.
  • Ghent University Hospital — Ghent
  • Hospital Sírio-Libanês — São Paulo
  • Princess Margaret Cancer Centre — Toronto
  • Herlev and Gentofte Hospital — Copenhagen
  • Helsinki University Hospital — Helsinki
  • Bordeaux Pellegrin University Hospital — Bordeaux
  • CHU Lille — Lille
  • Sorbonne Université — Paris
  • Heinrich Heine University Düsseldorf — Düsseldorf
  • Essen University Hospital — Essen
  • University Hospital Frankfurt — Frankfurt
  • Martini Klinik — Hamburg
  • San Raffaele Hospital — Milan

New York

  • NYU Langone — New York
  • Icahn School of Medicine (Mount Sinai) — New York
  • New York Presbyterian Hospital — New York

Minnesota

  • Mayo Clinic — Rochester

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-03-22
Est. Completion 2025-03-01
Phase NA

Sponsor

University College, London

6 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04571840

The ClinicalTrials.gov registry entry for NCT04571840 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University College, London, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions — of which Multiparametric MRI +/- prostate biopsy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04571840 reports 20 study locations spanning 3 distinct geographic areas — top geographies include Other, New York, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04571840 about?

NCT04571840 is a clinical study titled "Prostate Imaging Using MRI +/- Contrast Enhancement". This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that ...

What is the current status of trial NCT04571840?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-03-22. Estimated completion is 2025-03-01.

What conditions does trial NCT04571840 study?

This clinical trial studies the following conditions: Prostate Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04571840?

The interventions under investigation include: Multiparametric MRI +/- prostate biopsy (DIAGNOSTIC_TEST), Biparametric MRI +/- prostate biopsy (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04571840?

This trial is sponsored by University College, London, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04571840 being conducted?

This trial has 20 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial